How is medical device marketing different from typical B2B marketing?

Volume-based demand generation does not work when your total addressable market is a few hundred hospitals and each purchase requires committee approval. Medtech marketing is account-based: named targets, mapped stakeholders, and evidence built for each one.

Who has to approve a medical device purchase in a hospital?

Typically four groups: the physicians or clinicians who will use it, the value analysis committee, supply chain and procurement, and hospital leadership or finance. Any one of them can stop a deal, and each needs a different argument.

What belongs in a medical device evidence package?

Clinical outcomes data tied to your claims, an economic model showing the cost or throughput effect on the specific account, reimbursement and coding detail, safety and workflow information for clinical staff, and reference sites where the device is already in use.

What happens when marketing outruns the evidence?

Demand you cannot convert. Committees ask for proof the team does not have, the deal stalls in review, and the account gets harder to reopen. Build the evidence package before the outreach, not after the first meeting.

How to Market a MedTech Device to Hospital Committees

Short answer

Medical device marketing is account-based, not lead-based. You are not generating volume; you are moving a handful of hospitals through a committee decision where physicians, value analysis, supply chain, and finance all have to agree. The work is evidence, stakeholder mapping, and account-specific content — not campaigns.

Why medtech marketing is account-based, not lead-based

A hospital doesn't have a single buyer who clicks through a funnel and signs up. It has a physician who wants the clinical benefit, a value analysis committee that wants the economic case, a supply chain team that wants the logistics to work, and often a C-suite sponsor who wants it to fit the system's broader strategy. Marketing that only speaks to one of them — usually the physician — stalls the other three.

Case in point

Akili's EndeavorRx: when the story outruns the buying reality

FDA cleared EndeavorRx in 2020 as a prescription video game for pediatric ADHD, a genuinely novel achievement. But the product sat awkwardly between two markets: to regulators it was a medical device, to physicians a treatment, to parents it still looked and felt like a video game.

That gap mattered commercially. Software carries an expectation of being easy to try and cheap to access, while a prescription product carries a physician, a payer, and a pharmacy-like distribution path. Many payers weren't structured to evaluate a "prescription video game" at all, so reimbursement lagged and prescribing stayed cautious. By 2023 Akili was cutting staff and pivoting to a direct-to-consumer model; in 2024 it was acquired by Virtual Therapeutics for about $34 million.

The clinical evidence was real. The marketing question — who prescribes it, who pays for it, who explains it to a skeptical parent — was never fully answered before the product had to scale.

The four audiences, and they all have to say yes

A medical device marketing strategy is really four strategies that have to agree with each other.

Physicians

Care about clinical evidence and fit with how they already practice.

Value analysis committees

Care about total cost of ownership, not list price — and want an economic model, not a feature list.

Supply chain and procurement

Care about logistics, service, and whether the product creates operational burden.

Hospital leadership

Cares about whether this fits the system's broader clinical and financial strategy.

Case in point

Butterfly iQ+: the clinical story wasn't the blocker

Butterfly Network's handheld ultrasound has an obvious clinical case — bringing imaging to the patient instead of the patient to the imaging suite. The harder part of handheld ultrasound adoption, a pattern well documented across point-of-care ultrasound programs generally, shows up after pilots end: radiology wants quality assurance and oversight, clinicians worry about extra documentation time, and administrators focus on reimbursement, compliance, and cybersecurity.

None of those groups is the target of a launch built around the clinical story. Butterfly's later emphasis on governance tooling, credentialing, and enterprise deployment support speaks to them directly, and structured rollouts have produced hard numbers — Butterfly's own published case study with University of Rochester Medical Center reports a 116% increase in ultrasound charge capture. The device didn't change. Who the marketing had to convince did.

Building the evidence package

The evidence a hospital actually needs is rarely just the clinical study. It's a package: the clinical case, the economic case (what does this cost or save, and who captures that), and the operational case (what does adopting this actually require of staff, workflow, and existing systems). Skip any one of the three and the product reads as a demo, not a decision-ready purchase.

Clinical case

Evidence that the device performs as labeled, in a population the account recognizes as its own.

Economic case

A one-page model a value analysis reviewer can use — cost, savings, and who captures them.

Operational case

What adoption asks of staff, workflow, IT, and service, stated before anyone has to discover it.

This is also where marketing and market access blur together in medtech in a way they don't in most industries. A campaign that generates physician enthusiasm but no economic model for the value analysis committee has generated interest, not a sale.

Content and outreach that actually gets meetings

Generic awareness content — blog posts optimized for broad traffic, brochures that repeat the label — rarely moves a hospital account forward, because the audiences above aren't browsing. They're evaluating a specific decision for a specific institution.

What works instead: account-specific evidence briefs that name the hospital's own procedure volume or patient population, a clear one-page economic model a value analysis reviewer can actually use, and outreach timed to something real — a competitor's install base is aging, a payer policy just changed, a clinical champion just published. That kind of targeting requires knowing things about each account before the first meeting, not generic segment-level assumptions.

The intelligence question

Every audience above needs a different piece of evidence, and building that evidence by hand for each account is exactly the bottleneck that keeps medtech marketing generic instead of account-specific.

RevWorx surfaces the account-level intelligence — procedure volume, competitive install base, KOL signals, payer position — that a real account-based campaign needs, so the evidence package for each hospital is built from real data instead of reused boilerplate. See how that fits the wider picture in our medical device commercialization strategy page, or start with the high-level guide to medical device commercialization.

Sources and notes

Akili / EndeavorRx: FDA clearance (June 2020), the 2023 layoffs and pivot to a consumer model, and the 2024 acquisition by Virtual Therapeutics for approximately $34 million are publicly reported. See coverage in MedTech Dive and Axios.
Butterfly Network / Butterfly iQ+: the 116% charge-capture improvement at University of Rochester Medical Center comes from Butterfly Network's published case study. The adoption objections described here are presented as a pattern common to point-of-care ultrasound programs generally, not a documented account of one company's commercial history.

Frequently asked questions

How is medical device marketing different from typical B2B marketing?: Volume-based demand generation does not work when your total addressable market is a few hundred hospitals and each purchase requires committee approval. Medtech marketing is account-based: named targets, mapped stakeholders, and evidence built for each one.
Who has to approve a medical device purchase in a hospital?: Typically four groups: the physicians or clinicians who will use it, the value analysis committee, supply chain and procurement, and hospital leadership or finance. Any one of them can stop a deal, and each needs a different argument.
What belongs in a medical device evidence package?: Clinical outcomes data tied to your claims, an economic model showing the cost or throughput effect on the specific account, reimbursement and coding detail, safety and workflow information for clinical staff, and reference sites where the device is already in use.
What happens when marketing outruns the evidence?: Demand you cannot convert. Committees ask for proof the team does not have, the deal stalls in review, and the account gets harder to reopen. Build the evidence package before the outreach, not after the first meeting.